Literature DB >> 17328727

Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors.

M Masiá1, F Gutiérrez2, S Padilla2, B Soldán2, C Mirete2, C Shum3, I Hernández4, G Royo5, A Martin-Hidalgo2.   

Abstract

The aim of this study was to characterise community-acquired pneumonia (CAP) caused by atypical pathogens by combining distinctive clinical and epidemiological features and novel biological markers. A population-based prospective study of consecutive patients with CAP included investigation of biomarkers of bacterial infection, e.g., procalcitonin, C-reactive protein and lipopolysaccharide-binding protein (LBP) levels. Clinical, radiological and laboratory data for patients with CAP caused by atypical pathogens were compared by univariate and multivariate analysis with data for patients with typical pathogens and patients from whom no organisms were identified. Two predictive scoring models were developed with the most discriminatory variables from multivariate analysis. Of 493 patients, 94 had CAP caused by atypical pathogens. According to multivariate analysis, patients with atypical pneumonia were more likely to have normal white blood cell counts, have repetitive air-conditioning exposure, be aged <65 years, have elevated aspartate aminotransferase levels, have been exposed to birds, and have lower serum levels of LBP. Two different scoring systems were developed that predicted atypical pathogens with sensitivities of 35.2% and 48.8%, and specificities of 93% and 91%, respectively. The combination of selected patient characteristics and laboratory data identified up to half of the cases of atypical pneumonia with high specificity, which should help clinicians to optimise initial empirical therapy for CAP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17328727     DOI: 10.1111/j.1469-0691.2006.01629.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  12 in total

1.  Should procalcitonin be used as a routine biomarker of bacterial infection?

Authors:  R R Das
Journal:  Infection       Date:  2012-03-10       Impact factor: 3.553

2.  Prognostic value of procalcitonin in Legionella pneumonia.

Authors:  J Haeuptle; R Zaborsky; R Fiumefreddo; A Trampuz; I Steffen; R Frei; M Christ-Crain; B Müller; P Schuetz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-02       Impact factor: 3.267

Review 3.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ.

Authors:  Katrin Zobel; Peter Martus; Mathias W Pletz; Santiago Ewig; Michael Prediger; Tobias Welte; Frank Bühling
Journal:  BMC Pulm Med       Date:  2012-02-20       Impact factor: 3.317

5.  Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial.

Authors:  Mar Masiá; Sergio Padilla; Victoria Ortiz de la Tabla; Matilde González; Cristina Bas; Félix Gutiérrez
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

6.  Rapid clinical diagnosis of Legionnaires' disease during the "herald wave" of the swine influenza (H1N1) pandemic: the Legionnaires' disease triad.

Authors:  Burke A Cunha; Nardeen Mickail; Uzma Syed; Stephanie Strollo; Marianne Laguerre
Journal:  Heart Lung       Date:  2010 May-Jun       Impact factor: 2.210

Review 7.  Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias.

Authors:  Burke A Cunha
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

Review 8.  Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia.

Authors:  Kay Wang; Peter Gill; Rafael Perera; Anne Thomson; David Mant; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

9.  Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection.

Authors:  Paul Robert Ingram; Tim Inglis; David Moxon; David Speers
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

10.  Atypical pneumonia--time to breathe new life into a useful term?

Authors:  David R Murdoch; Stephen T Chambers
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.